Starwatch: Venus will pass through the ‘golden gate' of two star clusters
It references two star clusters in the constellation Taurus, the Bull. The Hydes and the Pleiades lie on either side of the ecliptic, which is the plane of the solar system. As such, the sun, the moon and the planets all follow this line in their passage through the sky. The constellations the ecliptic passes through are known as the zodiacal constellations, referred to in popular culture as the signs of the zodiac.
The chart shows the view looking east-north-east from London at 3.30am BST in the pre-dawn twilight of 8 July 2025. On this day, Venus will be approaching the 'gate'. On subsequent mornings, the brilliant planet will move across the invisible line between the two clusters and on 12 and 13 July, it will clip the top of the Hyades star cluster, appearing 3 degrees away from the star Aldebaran.
Venus will be a brilliant white beacon in the morning sky, contrasting with the blood-red light from Aldebaran, which represents the eye of the bull.
The conjunction will also be easily visible from the southern hemisphere.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
18 minutes ago
- The Guardian
The Guardian view on Britain's AI strategy: the risk is that it is dependency dressed up in digital hype
There was a time when Britain aspired to be a leader in technology. These days, it seems content to be a willing supplicant – handing over its data, infrastructure and public services to US tech giants in exchange for the promise of a few percentage points of efficiency gains. Worryingly, the artificial intelligence strategy of Sir Keir Starmer's government appears long on rhetoric, short on sovereignty and built on techno-utopian assumptions. Last week Peter Kyle, the technology secretary, was promoting the use of AI-generated discharge letters in the NHS. The tech, he said, will process complex conversations between doctors and patients, slashing paperwork and streamlining services. Ministers say that by applying AI across the public sector, the government can save £45bn. But step back and a more familiar pattern emerges. As Cecilia Rikap, a researcher at University College London, told the Politics Theory Other podcast, Britain risks becoming a satellite of the US tech industry – a nation whose public infrastructure serves primarily as a testing ground and data source for American AI models hosted on US-owned cloud computing networks. She warned that the UK should not become a site of 'extractivism', in which value – whether in the form of knowledge, labour or electricity – is supplied by Britain but monetised in the US. It's not just that the UK lacks a domestic cloud ecosystem. It's that the government's strategy does nothing to build one. The concern is that public data, much of it drawn from the NHS and local authorities, will be shovelled into models built and trained abroad. The value captured from that data – whether in the form of model refinement or product development – will accrue not to the British public, but to US shareholders. Even the promise of job creation appears shaky. Datacentres, the physical backbone of AI, are capital-intensive, energy-hungry, and each one employs only about 50 people. Meanwhile, Daron Acemoglu, the MIT economist and Nobel laureate, offers a still more sobering view: far from ushering in a golden age of labour augmentation, today's AI rollout is geared almost entirely toward labour displacement. Prof Acemoglu sees a fork: AI can empower workers – or replace them. Right now, it is doing the latter. Ministerial pledges of productivity gains may just mean fewer jobs – not better services. The deeper problem is one of imagination. A government serious about digital sovereignty might build a public cloud, fund open-source AI models and create institutions capable of steering technological development toward social ends. Instead, we are offered efficiency-by-outsourcing – an AI strategy where Britain provides the inputs and America reaps the returns. In a 2024 paper, Prof Acemoglu challenged Goldman Sachs' 10-year forecast that AI would lead to global growth of 7% – about $7tn – and estimated instead under $1tn in gains. Much of this would be captured by US big tech. There's nothing wrong with harnessing new technologies. But their deployment must not be structured in a way that entrenches dependency and hollows out public capacity. The Online Safety Act shows digital sovereignty can enforce national rules on global platforms, notably on porn sites. But current turmoil at the Alan Turing Institute suggests a deeper truth: the UK government is dazzled by American AI and has no clear plan of its own. Britain risks becoming not a tech pioneer, but a well-governed client state in someone else's digital empire. Do you have an opinion on the issues raised in this article? If you would like to submit a response of up to 300 words by email to be considered for publication in our letters section, please click here.
The Independent
an hour ago
- The Independent
‘Ozempic for dogs' may be the next big thing in pet health
With the runaway success of drugs like Ozempic and Mounjaro effectively helping humans slim down, researchers and biotech firms are now sniffing out a new frontier: weight-loss drugs for dogs. With up to 60 per cent of dogs in the UK estimated to be overweight or obese, the market for such drugs could be considerable. Okava, a San Francisco-based bio-pharma company which specialises in pet health, is planning to run trials for a drug designed to mimic the effects of Ozempic, with the goal to produce an implant-version for dogs, which lasts six-months at a time. According to estimates on the company's website, the current market for such a product could be worth $10bn, and they hope to have a canine weight-loss drug available as early as 2028 or 2029. In human weight-loss drugs, the active ingredient in Mounjaro is called tirzepatide, and in Ozempic, it is semaglutide. Both work in similar ways, mimicking a natural hormone called GLP-1. This hormone regulates blood sugar and appetite, ultimately leading people to feel fuller longer and reducing food intake. The challenge for biotech firms is to reproduce that effect in dogs – a species well-known for practically limitless gorging. The hope is that an Ozempic-style drug may reduce dogs' begging behaviour, which many owners find it difficult to resist rewarding. Often, lack of appetite in dogs is associated with illness, meaning developing an effective drug that doesn't appear to make pets seem unwell is a fine balance. One such drug, named Slentrol, was launched in 2007, but did not sell well, partly due to how owners' perceived their pets behaviour when on the medication. Okava's planned implant, called OKV-119, contains a GLP-1 mimic called exenatide. Michael Klotsman, Okava's chief executive, said he hoped dogs' behavioural changes from OKV-119 would be quite different from illness-related appetite loss. 'What owners should expect to see is their pet eating appropriate portions without the previous food obsession – they'll still eat regularly and show interest in meals, just without the excessive begging, scavenging or gulping behaviour,' he told The Guardian. But not all tails are wagging. Vets have suggested that in most cases, dog owners would be better off avoiding obesity in their dogs through more exercise and by restricting their pets' diets. Caroline Allen, Chief Veterinary Officer at the RSPCA told The Independent: 'A healthy diet and exercise is the best way to keep our pets happy and well but we understand that owners can sometimes struggle to manage their pets' weight. There is currently little information about proposed weight-loss implants or vaccinations for animals, and owners shouldn't rely on them becoming available. 'Before resorting to these sorts of interventions, owners should seek help from their vet about how to reduce their pet's weight with a good diet and providing lots of opportunities to exercise and play in ways that their pet will enjoy." She added: 'It may be that weight loss jabs or implants may have a role to play in future in very limited circumstances where animals are clinically unwell, but the best thing we can do is set healthy habits from the start so our pets can live the best life possible.'
The Guardian
3 hours ago
- The Guardian
Scientists claim to have unlocked ‘secret sauce' needed for fine chocolate
Whether you enjoy an aromatic bar with notes of caramel or something less fancy, chocolate can have many tastes. Now researchers say they have shed fresh light on a key ingredient that could open the door to new flavours. They claim to have unpicked how and why the bacteria and fungi involved in the fermentation of cocoa beans influence the flavour of chocolate. 'We understand now what microbes we need and what they're doing. And I think that opens up the opportunity … to be a lot more directed [about] how we make our chocolate in terms of its flavour.' said Prof David Salt, co-author of the work from the University of Nottingham. Writing in the journal Nature Microbiology, the team report how they studied beans fermented at cocoa farms in three different regions of Colombia – Santander, Huila and Antioquia. The researchers found that while the fermentation process was similar for the Santander and Huila farms, the beans at the Antioquia farm showed different temperature and pH patterns, which was most probably down to the presence and activity of a different group of microbes. Further research revealed that while cocoa liquor made from the beans at Santander and Huila farms had fruity, floral, citrus notes – similar to the characteristics of a fine flavour cocoa from Madagascar – the cocoa liquor made from the beans at Antioquia lacked the fruity, floral, citrus flavours, in some ways resembling the liquor from fermented beans from the Ivory Coast and Ghana that are used in bulk chocolate production. The team then used genetic sequencing to identify the microbes involved in cocoa bean fermentation from multiple sites in Colombia and beyond, explore the genes they contained, and hence identify the flavour substances they could produce during fermentation. As a result, the researchers identified nine microbes that together were predicted to produce the notes of a fine flavour cocoa. They then introduced this community to sterile cocoa beans, and allowed them to ferment. The upshot, said Salt, was a cocoa with floral, fruity and citrus notes and a recognisable cocoa flavour but with reduced astringency and bitterness. 'I call it the secret sauce,' said Salt. He said the findings could have a number of applications, including helping cocoa farmers find ways to promote the presence of the key microbes during fermentation to ensure they can reproduce conditions required for high quality cocoa. It could even help with the current crisis in the cost of chocolate, said Salt, suggesting that if cocoa farmers were able to produce more flavourful cocoa, less would be needed during production. And there was another possibility. 'You could bring in either inoculums [of microbes] that could bring in particular flavours, new flavours that you just don't see normally in cocoa,' he said. 'Or you could actually come up with strategies to bias a fermentation, to come up with new flavours.'
